Company Profile

ALKEM LABORATORIES LTD.

NSE : ALKEMBSE : 539523ISIN CODE : INE540L01014Industry : Pharmaceuticals & DrugsHouse : Private
BSE4001.8537.65 (+0.95 % )
PREV CLOSE (Rs.) 3964.20
OPEN PRICE (Rs.) 3958.00
BID PRICE (QTY) 0.00 (0 )
OFFER PRICE (QTY) 0.00 (0 )
VOLUME 8264
TODAY'S LOW / HIGH (Rs.)3950.00 4067.70
52 WK LOW / HIGH (Rs.)2544.25 3979.5
NSE4003.10 39.9 (+1.01 % )
PREV CLOSE(Rs.) 3963.20
OPEN PRICE (Rs.) 3962.00
BID PRICE (QTY) 4003.10 (167 )
OFFER PRICE (QTY) 0.00 (0 )
VOLUME 289454
TODAY'S LOW / HIGH(Rs.) 3950.10 4070.00
52 WK LOW / HIGH (Rs.)2540.05 3978.85

Smart Quotes

1D 1M 3M 1Y 3Y 5Y
STOCK SUMMARY
Trade Value (Rs. in Lacs) 0.00
Dividend Yield(%) 0.75
TTM EPS (Rs.) 144.54
P/E Ratio 27.69
Book Value (Rs.) 677.04
Face Value (Rs.) 2
MCap (Rs. in Mn) 478481.20
Price/Earning (TTM) 24.78
Price/Sales (TTM) 6.01
Price/Book (MRQ) 5.91
PAT Margin (%) 22.16
ROCE (%) 23.42
Incorporation Year : 1973

Management Info :

Basudeo N Singh - Chairman Sandeep Singh - Managing Director

Registered Office :

Address : Alkem House,Senapati Bapat Marg,Lower Parel,
Mumbai,
Maharashtra-400013

Phone : 022 3982 9999

Website : www.alkemlabs.com

Registrar's Details : Link Intime India Pvt Ltd.
C 101, 247 Park,LBS Marg,Vikhroli (West),Mumbai
Listing : BSE, NSE
NEWS More
20Sep09-20-2021$Alkem Laboratories gets nod to close operations at Baddi facility Alkem Laboratories gets nod

Alkem Laboratories has received approval to close the operations at Beta Block (Unit II) manufacturing facility located at Baddi. The Beta Block (Unit-II) manufacturing facility at Baddi mainly catered to domestic market for Injections and was significantly underutilized. To avoid operating expenditure in Baddi, it is decided to discontinue the manufacturing operations at this facility, pursuant to the date of closure this facility shall be used as a warehouse.

Alkem Laboratories is a leading Indian pharmaceutical company with global operations, engaged in the development, manufacture and sale of pharmaceutical and nutraceutical products. The company produces branded generics, generic drugs, active pharmaceutical Ingredients (APIs) and nutraceuticals, which it markets in India and International markets.

Alkem Laboratories has received approval to close the operation..
20Sep09-20-2021$Alkem Laboratories informs about disclosure Alkem Laboratories informs a

Alkem Laboratories has informed that the Board of Directors of the Company vide Circular Resolution passed on 16th September, 2021 approved the closure of operations at Beta Block (Unit II) manufacturing facility located at Baddi. Details required to be submitted under Regulation 30 of SEBI Listing Regulations are enclosed.

The above information is a part of company’s filings submitted to BSE.

Alkem Laboratories has informed that the Board of Directors of..
20Sep09-20-2021$Alkem Laboratories tumbles on getting nod to close operations at Baddi facility Alkem Laboratories tumbles o

Alkem Laboratories is currently trading at Rs. 3781.80, down by 51.75 points or 1.35% from its previous closing of Rs. 3833.55 on the BSE.

The scrip opened at Rs. 3815.55 and has touched a high and low of Rs. 3815.55 and Rs. 3747.70 respectively. So far 2493 shares were traded on the counter.

The BSE group 'A' stock of face value Rs. 2 has touched a 52 week high of Rs. 3946.45 on 02-Sep-2021 and a 52 week low of Rs. 2544.25 on 24-Mar-2021.

Last one week high and low of the scrip stood at Rs. 3895.60 and Rs. 3746.70 respectively. The current market cap of the company is Rs. 45076.01 crore.

The promoters holding in the company stood at 58.84%, while Institutions and Non-Institutions held 18.99% and 22.17% respectively.

Alkem Laboratories has received approval to close the operations at Beta Block (Unit II) manufacturing facility located at Baddi. The Beta Block (Unit-II) manufacturing facility at Baddi mainly catered to domestic market for Injections and was significantly underutilized. To avoid operating expenditure in Baddi, it is decided to discontinue the manufacturing operations at this facility, pursuant to the date of closure this facility shall be used as a warehouse.

Alkem Laboratories is a leading Indian pharmaceutical company with global operations, engaged in the development, manufacture and sale of pharmaceutical and nutraceutical products. The company produces branded generics, generic drugs, active pharmaceutical Ingredients (APIs) and nutraceuticals, which it markets in India and International markets.

Alkem Laboratories is currently trading at Rs. 3781.80, down by..
07Aug08-07-2021$Alkem Laboratories reports 11% rise in Q1 consolidated net profit Alkem Laboratories reports 1

Alkem Laboratories has reported results for first quarter ended June 30, 2021.

The company has reported a rise of 10.12% in its net profit at Rs 469.27 crore for the quarter under review as compared to net profit of Rs 426.16 crore for the same quarter in the previous year. Total income of the company increased by 46.40% at Rs 2,317.88 crore for Q1FY22 as compared Rs 1583.30 crore for the corresponding quarter previous year.

On the consolidated basis, the company has reported a rise of 10.93% in its net profit attributed to the owners at Rs 468.12 crore for the quarter under review as compared to net profit of Rs 422.01 crore for the same quarter in the previous year. Total income of the company increased by 35.71% at Rs 2,778.01 crore for Q1FY22 as compared Rs 2,046.99 crore for the corresponding quarter previous year.

Alkem Laboratories has reported results for first quarter ended..
04Aug08-04-2021$Alkem Laboratories informs about press release Alkem Laboratories informs a

Alkem Laboratories has informed that the Company has launched Ibuprofen and Famotidine Tablets in the United States, following an approval from the United States Food and Drug Administration (US FDA). A press release in this regard is enclosed on 4th August 2021 titled ‘Alkem Launches Ibuprofen and Famotidine Tablets in the United States’.

The above information is a part of company’s filings submitted to BSE.


Alkem Laboratories has informed that the Company has launched I..
Financials More
Rs. in Millions
QTR Jun 21 ANNUAL 21
Net Profit4692.716850.8
Gross Profit 5290 18843
Operating Profit 5897.821389.4
Net Sales 22786.772196.8
ROLLING FORWARD P/E (EOD)
EVENT CALENDAR
peer group More
JB Chem & Pharma (BSE)
 1836.10 (5.26%)
M.Cap ( in Cr)
14189.77
Kwality Pharma (BSE)
 688.70 (4.99%)
M.Cap ( in Cr)
714.61
Hester Biosciences (BSE)
 2518.75 (0.91%)
M.Cap ( in Cr)
2142.67
Procter&Gamble Healt (BSE)
 5381.55 (0.34%)
M.Cap ( in Cr)
8933.04
Chandra Bhagat Pharm (BSE)
 124.55 (14.27%)
M.Cap ( in Cr)
93.97
Shareholding Pattern More
MUTUAL FUNDS/UTI 8.4 %
PROMOTERS 58.84 %
FI/BANKS/INSURANCE 5.88 %
NON-INSTITUTION 22.17 %
GOVERNMENT 0 %
FII 0 %
F & O Quotes